181 related articles for article (PubMed ID: 36340185)
1. Sorafenib-Entrapped, Self-Assembled Pullulan-Stearic Acid Biopolymer-Derived Drug Delivery System to PLC/PRF/5 Hepatocellular Carcinoma Model.
Chirayil TJ; Kumar GSV
Int J Nanomedicine; 2022; 17():5099-5116. PubMed ID: 36340185
[TBL] [Abstract][Full Text] [Related]
2. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.
Pranatharthiharan S; Patel MD; Malshe VC; Pujari V; Gorakshakar A; Madkaikar M; Ghosh K; Devarajan PV
Drug Deliv; 2017 Nov; 24(1):20-29. PubMed ID: 28155331
[TBL] [Abstract][Full Text] [Related]
3. Efficient delivery of paclitaxel into ASGPR over-expressed cancer cells using reversibly stabilized multifunctional pullulan nanoparticles.
Huang L; Wang Y; Ling X; Chaurasiya B; Yang C; Du Y; Tu J; Xiong Y; Sun C
Carbohydr Polym; 2017 Mar; 159():178-187. PubMed ID: 28038747
[TBL] [Abstract][Full Text] [Related]
4.
Sun R; Fang L; Lv X; Fang J; Wang Y; Chen D; Wang L; Chen J; Qi Y; Tang Z; Zhang J; Tian Y
Drug Deliv; 2021 Dec; 28(1):2071-2084. PubMed ID: 34595970
[TBL] [Abstract][Full Text] [Related]
5. Versatile redox-sensitive pullulan nanoparticles for enhanced liver targeting and efficient cancer therapy.
Huang L; Chaurasiya B; Wu D; Wang H; Du Y; Tu J; Webster TJ; Sun C
Nanomedicine; 2018 Apr; 14(3):1005-1017. PubMed ID: 29409820
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy.
Zheng G; Zhao R; Xu A; Shen Z; Chen X; Shao J
Eur J Pharm Sci; 2018 Jan; 111():492-502. PubMed ID: 29107835
[TBL] [Abstract][Full Text] [Related]
7. Re-programming pullulan for targeting and controlled release of doxorubicin to the hepatocellular carcinoma cells.
Balasso A; Salmaso S; Pontisso P; Rosato A; Quarta S; Malfanti A; Mastrotto F; Caliceti P
Eur J Pharm Sci; 2017 May; 103():104-115. PubMed ID: 28192167
[TBL] [Abstract][Full Text] [Related]
8. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of pectin-deoxycholic acid conjugate for targeted delivery of anticancer drugs in hepatocellular carcinoma.
Varshosaz J; Sadri F; Rostami M; Mirian M; Taymouri S
Int J Biol Macromol; 2019 Oct; 139():665-677. PubMed ID: 31377298
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in Asialoglycoprotein Receptor and Glycyrrhetinic Acid Receptor-Mediated and/or pH-Responsive Hepatocellular Carcinoma- Targeted Drug Delivery.
Li YL; Zhu XM; Liang H; Orvig C; Chen ZF
Curr Med Chem; 2021; 28(8):1508-1534. PubMed ID: 32368967
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib encapsulated in nanocarrier functionalized with glypican-3 specific peptide for targeted therapy of hepatocellular carcinoma.
Feng S; Zhou J; Li Z; Appelman HD; Zhao L; Zhu J; Wang TD
Colloids Surf B Biointerfaces; 2019 Dec; 184():110498. PubMed ID: 31536939
[TBL] [Abstract][Full Text] [Related]
12. pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma.
Wang Y; Chen H; Liu Y; Wu J; Zhou P; Wang Y; Li R; Yang X; Zhang N
Biomaterials; 2013 Sep; 34(29):7181-90. PubMed ID: 23791500
[TBL] [Abstract][Full Text] [Related]
13. Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration.
Huang Y; Hu L; Huang S; Xu W; Wan J; Wang D; Zheng G; Xia Z
Int J Nanomedicine; 2018; 13():8309-8323. PubMed ID: 30584302
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of stearic acid-pullulan nanoparticles.
Kim IS; Oh IJ
Arch Pharm Res; 2010 May; 33(5):761-7. PubMed ID: 20512475
[TBL] [Abstract][Full Text] [Related]
15. Core-shell nanoparticles based on pullulan and poly(β-amino) ester for hepatoma-targeted codelivery of gene and chemotherapy agent.
Liu Y; Wang Y; Zhang C; Zhou P; Liu Y; An T; Sun D; Zhang N; Wang Y
ACS Appl Mater Interfaces; 2014; 6(21):18712-20. PubMed ID: 25289563
[TBL] [Abstract][Full Text] [Related]
16. Design of a Novel Nucleus-Targeted NLS-KALA-SA Nanocarrier to Delivery Poorly Water-Soluble Anti-Tumor Drug for Lung Cancer Treatment.
Yan C; Shi W; Gu J; Lee RJ; Zhang Y
J Pharm Sci; 2021 Jun; 110(6):2432-2441. PubMed ID: 33412169
[TBL] [Abstract][Full Text] [Related]
17. Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma.
Varshosaz J; Hassanzadeh F; Sadeghi H; Khadem M
J Liposome Res; 2012 Sep; 22(3):224-36. PubMed ID: 22385296
[TBL] [Abstract][Full Text] [Related]
18. Galactosylated pullulan-curcumin conjugate micelles for site specific anticancer activity to hepatocarcinoma cells.
Sarika PR; James NR; Nishna N; Anil Kumar PR; Raj DK
Colloids Surf B Biointerfaces; 2015 Sep; 133():347-55. PubMed ID: 26133239
[TBL] [Abstract][Full Text] [Related]
19. Novel folated and non-folated pullulan bioconjugates for anticancer drug delivery.
Scomparin A; Salmaso S; Bersani S; Satchi-Fainaro R; Caliceti P
Eur J Pharm Sci; 2011 Apr; 42(5):547-58. PubMed ID: 21371555
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
Zhao R; Li T; Zheng G; Jiang K; Fan L; Shao J
Biomaterials; 2017 Oct; 143():1-16. PubMed ID: 28755539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
